250-OR: Hypoproliferative CD8 Effector Memory (EM) Subsets Are Linked to Preservation of C-Peptide in Alefacept-Treated Recent-Onset Type 1 Diabetes (T1D) Subjects

Twenty-two patients who had an episode of transfusion-associated hepatitis not positive for hepatitis B antigen were examined for development of antibody to hepatitis A and B antigens, cytomegalovirus and Epstein-Barr virus. Antibody response to the 27-nm virus-like hepatitis A antigen was measured by immune electron microscopy. In none of the 22 patients studied did serologic evidence of infection with hepatitis A virus develop during the study period. Nine of the 22 patients had antibody responses to cytomegalovirus, but it was difficult to relate these seroconversions to their hepatitis. In addition, all 22 patients had pre-existing antibody to the Epstein-Barr virus. It seems likely that at least a proportion of such antigen-negative transfusion-associated hepatitis is caused by other infectious agents, not yet identified. (N Engl J Med 292:767–770, 1975)

Annals of the New York Academy of SciencesVolume 143, Issue 1 p. 484-496 EPIDEMIOLOGY OF M. PNEUMONIAE INFECTION IN MILITARY RECRUITS R. M. Chanock, R. M. Chanock Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, Bethesda, Md.Search for more papers by this authorH. H. Fox, H. H. Fox Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, Bethesda, Md.Search for more papers by this authorW. D. James, W. D. James Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, Bethesda, Md.Search for more papers by this authorR. R. Gutekunst, R. R. Gutekunst Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, Bethesda, Md.Search for more papers by this authorR. J. White, R. J. White Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, Bethesda, Md.Search for more papers by this authorL. B. Senterfit, L. B. Senterfit Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, Bethesda, Md.Search for more papers by this author R. M. Chanock, R. M. Chanock Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, Bethesda, Md.Search for more papers by this authorH. H. Fox, H. H. Fox Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, Bethesda, Md.Search for more papers by this authorW. D. James, W. D. James Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, Bethesda, Md.Search for more papers by this authorR. R. Gutekunst, R. R. Gutekunst Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, Bethesda, Md.Search for more papers by this authorR. J. White, R. J. White Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, Bethesda, Md.Search for more papers by this authorL. B. Senterfit, L. B. Senterfit Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Infectious Diseases, Bethesda, Md.Search for more papers by this author First published: July 1967 https://doi.org/10.1111/j.1749-6632.1967.tb27692.xCitations: 43AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Citing Literature Volume143, Issue1Biology of the MycoplasmaJuly 1967Pages 484-496 RelatedInformation

Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies

Vox SanguinisVolume 20, Issue 5 p. 464-465 Hepatitis-Associated Antigen and Antibody in Cold Ethanol Fractionates of Human Blood P. Holland, P. Holland Clinical Center Blood Bank, NIH, National Institute of Allergy and Infectious Diseases, Bethesda, Md., and Department of Public Health, Lansing, Mich.Search for more papers by this authorH. Alter, H. Alter Clinical Center Blood Bank, NIH, National Institute of Allergy and Infectious Diseases, Bethesda, Md., and Department of Public Health, Lansing, Mich.Search for more papers by this authorR. Purcell, R. Purcell Clinical Center Blood Bank, NIH, National Institute of Allergy and Infectious Diseases, Bethesda, Md., and Department of Public Health, Lansing, Mich.Search for more papers by this authorJ. T. Sgouris, J. T. Sgouris Clinical Center Blood Bank, NIH, National Institute of Allergy and Infectious Diseases, Bethesda, Md., and Department of Public Health, Lansing, Mich.Search for more papers by this author P. Holland, P. Holland Clinical Center Blood Bank, NIH, National Institute of Allergy and Infectious Diseases, Bethesda, Md., and Department of Public Health, Lansing, Mich.Search for more papers by this authorH. Alter, H. Alter Clinical Center Blood Bank, NIH, National Institute of Allergy and Infectious Diseases, Bethesda, Md., and Department of Public Health, Lansing, Mich.Search for more papers by this authorR. Purcell, R. Purcell Clinical Center Blood Bank, NIH, National Institute of Allergy and Infectious Diseases, Bethesda, Md., and Department of Public Health, Lansing, Mich.Search for more papers by this authorJ. T. Sgouris, J. T. Sgouris Clinical Center Blood Bank, NIH, National Institute of Allergy and Infectious Diseases, Bethesda, Md., and Department of Public Health, Lansing, Mich.Search for more papers by this author First published: May 1971 https://doi.org/10.1111/j.1423-0410.1971.tb01825.xCitations: 4AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article.Citing Literature Volume20, Issue5May 1971Pages 464-465 RelatedInformation

Biotechnology and BioengineeringVolume 11, Issue 5 p. 1037-1041 Communications to the EditorFree Access Solubility of endotoxin and stability of its biological activity in organic liquids T. D. Perrine, T. D. Perrine Laboratory of Chemistry, National Institute of Arthritis and Metabolic Diseases, Bethesda, Maryland 20014Search for more papers by this authorJ. Kyle, J. Kyle U.S. Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratory, Hamilton, Montana 59840Search for more papers by this authorK. C. Milner, K. C. Milner U.S. Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratory, Hamilton, Montana 59840Search for more papers by this authorE. Ribi, E. Ribi U.S. Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratory, Hamilton, Montana 59840Search for more papers by this author T. D. Perrine, T. D. Perrine Laboratory of Chemistry, National Institute of Arthritis and Metabolic Diseases, Bethesda, Maryland 20014Search for more papers by this authorJ. Kyle, J. Kyle U.S. Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratory, Hamilton, Montana 59840Search for more papers by this authorK. C. Milner, K. C. Milner U.S. Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratory, Hamilton, Montana 59840Search for more papers by this authorE. Ribi, E. Ribi U.S. Department of Health, Education and Welfare, Public Health Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Rocky Mountain Laboratory, Hamilton, Montana 59840Search for more papers by this author First published: September 1969 https://doi.org/10.1002/bit.260110525Citations: 1AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume11, Issue5September 1969Pages 1037-1041 ReferencesRelatedInformation

Annals of the New York Academy of SciencesVolume 143, Issue 1 p. 384-389 GROWTH OF MYCOPLASMA PNEUMONIAE ON A GLASS SURFACE Norman L. Somerson, Norman L. Somerson Present address: Department of Medical Microbiology, Children's Hospital, Columbus, Ohio.Search for more papers by this authorWalter D. James, Walter D. James National Institute of Allergy and Infectious Diseases, U.S. Public Health Service, Bethesda, Md. IntroductionSearch for more papers by this authorBarbara E. Walls, Barbara E. Walls National Institute of Allergy and Infectious Diseases, U.S. Public Health Service, Bethesda, Md. IntroductionSearch for more papers by this authorRobert M. Chanock, Robert M. Chanock National Institute of Allergy and Infectious Diseases, U.S. Public Health Service, Bethesda, Md. IntroductionSearch for more papers by this author Norman L. Somerson, Norman L. Somerson Present address: Department of Medical Microbiology, Children's Hospital, Columbus, Ohio.Search for more papers by this authorWalter D. James, Walter D. James National Institute of Allergy and Infectious Diseases, U.S. Public Health Service, Bethesda, Md. IntroductionSearch for more papers by this authorBarbara E. Walls, Barbara E. Walls National Institute of Allergy and Infectious Diseases, U.S. Public Health Service, Bethesda, Md. IntroductionSearch for more papers by this authorRobert M. Chanock, Robert M. Chanock National Institute of Allergy and Infectious Diseases, U.S. Public Health Service, Bethesda, Md. IntroductionSearch for more papers by this author First published: July 1967 https://doi.org/10.1111/j.1749-6632.1967.tb27680.xCitations: 70 AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Citing Literature Volume143, Issue1Biology of the MycoplasmaJuly 1967Pages 384-389 RelatedInformation

Annals of the New York Academy of SciencesVolume 100, Issue 1 p. 569-583 ENZYMIC AND OTHER SIMILARITIES OF MELANOMA GRANULES AND MITOCHONDRIA H. G. du Buy, H. G. du Buy Laboratory of Biology and Viruses, National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md.Search for more papers by this authorJ. L. Showacre, J. L. Showacre Laboratory of Biology and Viruses, National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md.Search for more papers by this authorM. L. Hesselbach, M. L. Hesselbach Laboratory of Biology and Viruses, National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md.Search for more papers by this author H. G. du Buy, H. G. du Buy Laboratory of Biology and Viruses, National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md.Search for more papers by this authorJ. L. Showacre, J. L. Showacre Laboratory of Biology and Viruses, National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md.Search for more papers by this authorM. L. Hesselbach, M. L. Hesselbach Laboratory of Biology and Viruses, National Institute of Allergy and Infectious Diseases, Public Health Service, Bethesda, Md.Search for more papers by this author First published: February 1963 https://doi.org/10.1111/j.1749-6632.1963.tb42873.xCitations: 14AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume100, Issue1The Pigment Cell Molecular, Biological, and Clinical Aspects: Part IFebruary 1963Pages 569-583 RelatedInformation

Journal of Cellular and Comparative PhysiologyVolume 50, Issue 2 p. 219-240 Article Observations on the polysaccharides of aquatic snails† Patricia McMahon, Patricia McMahon U. S. Department of Health, Education, and Welfare Public Health Service National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda 14, MarylandSearch for more papers by this authorTheodor von Brand, Theodor von Brand U. S. Department of Health, Education, and Welfare Public Health Service National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda 14, MarylandSearch for more papers by this authorM. O. Nolan, M. O. Nolan U. S. Department of Health, Education, and Welfare Public Health Service National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda 14, MarylandSearch for more papers by this author Patricia McMahon, Patricia McMahon U. S. Department of Health, Education, and Welfare Public Health Service National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda 14, MarylandSearch for more papers by this authorTheodor von Brand, Theodor von Brand U. S. Department of Health, Education, and Welfare Public Health Service National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda 14, MarylandSearch for more papers by this authorM. O. Nolan, M. O. Nolan U. S. Department of Health, Education, and Welfare Public Health Service National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda 14, MarylandSearch for more papers by this author First published: October 1957 https://doi.org/10.1002/jcp.1030500206Citations: 42 † Part of the work reported herein was submitted by P. McMahon to the Graduate School of Georgetown University in partial fulfillment of the requirements for the degree of Master of Science. ‡ Laboratory of Tropical Diseases. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Citing Literature Volume50, Issue2October 1957Pages 219-240 RelatedInformation

The role of human leukocyte antigen E and G in HIV infection

CD4 T cells play a critical role in regulating CD8 T-cell responses during chronic viral infection. Several studies in animal models and humans have shown that the absence of CD4 T-cell help results in severe dysfunction of virus-specific CD8 T cells. However, whether function can be restored in already exhausted CD8 T cells by providing CD4 T-cell help at a later time remains unexplored. In this study, we used a mouse model of chronic lymphocytic choriomeningitis virus (LCMV) infection to address this question. Adoptive transfer of LCMV-specific CD4 T cells into chronically infected mice restored proliferation and cytokine production by exhausted virus-specific CD8 T cells and reduced viral burden. Although the transferred CD4 T cells were able to enhance function in exhausted CD8 T cells, these CD4 T cells expressed high levels of the programmed cell death (PD)-1 inhibitory receptor. Blockade of the PD-1 pathway increased the ability of transferred LCMV-specific CD4 T cells to produce effector cytokines, improved rescue of exhausted CD8 T cells, and resulted in a striking reduction in viral load. These results suggest that CD4 T-cell immunotherapy alone or in conjunction with blockade of inhibitory receptors may be a promising approach for treating CD8 T-cell dysfunction in chronic infections and cancer.

Data Safety Monitoring Boards primarily review accumulating data on clinical trials and provide recommendations to sponsors on whether a protocol should continue as planned, be modified, or be terminated. Data Safety Monitoring Boards often provide their recommendations based upon accumulating data to which only their members are given access. Despite the substantial responsibilities assumed by Data Safety Monitoring Board members, there is limited information in the literature about the unique knowledge they must possess and, consequently, the training content needs that are required in order for them to fulfill their obligations. This article describes how the National Institute of Allergy and Infectious Diseases identified the knowledge that Data Safety Monitoring Board members should acquire and the computer-based training they developed to address the learning needs of the National Institute of Allergy and Infectious Diseases assembled Data Safety Monitoring Board members. The National Institute of Allergy and Infectious Diseases conducted a comprehensive literature search and interviewed Data Safety Monitoring Board subject matter experts, including Data Safety Monitoring Board members and chairs from academic institutions, pharmaceutical companies, and the National Institutes of Health to (1) assess whether Data Safety Monitoring Board training is an identified need, (2) evaluate whether Data Safety Monitoring Board training has been developed, and (3) formulate suitable learning objectives. Data Safety Monitoring Board training modules were developed based on the identified learning objectives identified from the interviews. Three Data Safety Monitoring Board training modules were developed and formatted for web-based access, which is free of charge to the public at https://dsmblearningcenter.niaid.nih.gov. The modules include the following: an introduction to the objectives and purpose of Data Safety Monitoring Boards, the organization and responsibilities of Data Safety Monitoring Boards, and a review of statistical topics. The complex concepts that Data Safety Monitoring Board members must apply to their deliberations and decisions require practice and application that come through hands-on experience. To build competency in the Data Safety Monitoring Board member role, not only does a member need to understand these complex concepts but also the member must have the opportunity to practice and apply this knowledge to real-life situations. Additional resources to facilitate practice and application of the complex issues that Data Safety Monitoring Boards deal with should be considered. The computer-based training is targeted to new and inexperienced Data Safety Monitoring Board members. Ongoing learning opportunities should be developed for experienced Data Safety Monitoring Board members. Non-English training must also be considered. The National Institute of Allergy and Infectious Diseases identified that training is not widely available for Data Safety Monitoring Board members to build the unique knowledge and skills necessary to serve on Data Safety Monitoring Boards. Consequently, National Institute of Allergy and Infectious Diseases developed publicly available web-based Data Safety Monitoring Board training modules for new or inexperienced members. Additional tools and resources are needed to help Data Safety Monitoring Board members acquire the knowledge and skills to serve their critical function in clinical research and to maximize research participant protections.

The T1DAL clinical trial, NCT00965458, demonstrated that alefacept (LFA-3-Ig) treatment was associated with preservation of c-peptide in subjects with new-onset T1D. Previous analysis of peripheral blood from these subjects showed reduction of CD2-expressing lymphocytes, including memory T cell populations. We now have interrogated the islet antigen-specific (autoreactive) T cell profiles from subjects in this trial using single-cell mass cytometry in combination with peptide-loaded MHC class I tetramer (Tmr) staining. We then applied a new analytical method, DISCOV-R, for phenotyping rare cell subsets using a multiparameter clustering algorithm. As expected among polyclonal CD8+ T cells, alefacept treatment preferentially reduced memory subsets, particularly those with higher expression of CD2 (Helios- transitional memory, exhausted effector memory, and Helios- effector memory CD45RA+). Prior to treatment, autoreactive Tmr+ CD8+ T cells were phenotypically heterogeneous, with three prominent phenotypes across T1D subjects (CXCR3+ naïve, Helios- and Helios+ transitional memory). Following alefacept treatment, the overall frequencies of autoreactive cells did not consistently change; however, their phenotypes were altered. CD2-high CD8+ T cells were diminished; naïve cells were expanded; and notably, a stem cell-like memory phenotype, indicative of early memory with high proliferative potential but low effector function, was also substantially expanded among autoreactive cells in most individuals. Similar phenotypic alterations occurred among polyclonal CD8+ T cells, indicating that the effects were not limited to the islet-specific T cell population. These findings suggest that alefacept treatment alters the composition of autoreactive CD8+ T cells that are not depleted, and that phenotype, not just frequency, of autoreactive cells is an important consideration for development of other immunomodulatory therapies. Disclosure A.E. Wiedeman: None. V.S. Muir: Research Support; Self; Celgene Corporation. G.T. Nepom: Advisory Panel; Self; GlaxoSmithKline plc., Pfizer Inc. Research Support; Self; JDRF, National Institute of Allergy and Infectious Diseases. Other Relationship; Self; Diabetes UK. P. Linsley: None. S. Long: None.

Immunological ReviewsVolume 146, Issue 1 p. 5-19 Role of Extracellular ATP and P1 and P2 Classes of Purinergic Receptors in T-cell Development and Cytotoxic T Lymphocyte Effector Functions SERGEY APASOV, SERGEY APASOV Laboratory of Immunology, National Institute of Allergy and Infections Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.Search for more papers by this authorMASAHIRO KOSHIBA, MASAHIRO KOSHIBA Laboratory of Immunology, National Institute of Allergy and Infections Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.Search for more papers by this authorFRANK REDEGELD, FRANK REDEGELD Laboratory of Immunology, National Institute of Allergy and Infections Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. Department of Pharmacology, Faculty of Pharmacy, Utrecht University, P.O. Box 80.082, 3508 TB Utrecht, The Netherlands.Search for more papers by this authorMICHAIL V. SITKOVSKY, Corresponding Author MICHAIL V. SITKOVSKY Laboratory of Immunology, National Institute of Allergy and Infections Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.Michail V. Sitkovsky, Bldg. 10, Room 11N-311, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. Tel: 301-496-54-95; Fax: 301-496-02-22.Search for more papers by this author SERGEY APASOV, SERGEY APASOV Laboratory of Immunology, National Institute of Allergy and Infections Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.Search for more papers by this authorMASAHIRO KOSHIBA, MASAHIRO KOSHIBA Laboratory of Immunology, National Institute of Allergy and Infections Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.Search for more papers by this authorFRANK REDEGELD, FRANK REDEGELD Laboratory of Immunology, National Institute of Allergy and Infections Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. Department of Pharmacology, Faculty of Pharmacy, Utrecht University, P.O. Box 80.082, 3508 TB Utrecht, The Netherlands.Search for more papers by this authorMICHAIL V. SITKOVSKY, Corresponding Author MICHAIL V. SITKOVSKY Laboratory of Immunology, National Institute of Allergy and Infections Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.Michail V. Sitkovsky, Bldg. 10, Room 11N-311, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. Tel: 301-496-54-95; Fax: 301-496-02-22.Search for more papers by this author First published: August 1995 https://doi.org/10.1111/j.1600-065X.1995.tb00680.xCitations: 77 AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Citing Literature Volume146, Issue1August 1995Pages 5-19 RelatedInformation

Antiviral Therapeutics: Key to Curbing the COVID-19 Pandemic

Reviews in Medical VirologyVolume 6, Issue 2 p. 85-96 Research Article Vaccine Therapy for Herpes Simplex Virus Infections: An Historical Perspective R. McKenzie, R. McKenzie Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-1888, USASearch for more papers by this authorS. E. Straus, S. E. Straus Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-1888, USASearch for more papers by this author R. McKenzie, R. McKenzie Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-1888, USASearch for more papers by this authorS. E. Straus, S. E. Straus Medical Virology Section, Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-1888, USASearch for more papers by this author First published: June 1996 https://doi.org/10.1002/(SICI)1099-1654(199606)6:2<85::AID-RMV167>3.0.CO;2-ECitations: 5AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Citing Literature Volume6, Issue2June 1996Pages 85-96 RelatedInformation